172 related articles for article (PubMed ID: 20058135)
1. UFT and S-1 for treatment of primary lung cancer.
Tanaka F; Wada H; Fukushima M
Gen Thorac Cardiovasc Surg; 2010 Jan; 58(1):3-13. PubMed ID: 20058135
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
[TBL] [Abstract][Full Text] [Related]
3. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Miyoshi T; Kondo K; Toba H; Yoshida M; Fujino H; Kenzaki K; Sakiyama S; Takehisa M; Tangoku A
Anticancer Res; 2007; 27(4C):2641-8. PubMed ID: 17695427
[TBL] [Abstract][Full Text] [Related]
6. A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.
Tsuboi M; Kondo K; Takizawa H; Kawakita N; Sawada T; Toba H; Kawakami Y; Yoshida M; Ishikura H; Kimura S; Tangoku A
J Med Invest; 2018; 65(1.2):90-95. PubMed ID: 29593202
[TBL] [Abstract][Full Text] [Related]
7. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
8. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
9. Uracil-tegafur in gastric carcinoma: a comprehensive review.
Takiuchi H; Ajani JA
J Clin Oncol; 1998 Aug; 16(8):2877-85. PubMed ID: 9704742
[TBL] [Abstract][Full Text] [Related]
10. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
11. ABCC11 gene polymorphism as a potential predictive biomarker for an oral 5-fluorouracil derivative drug S-1 treatment in non-small cell lung cancer.
Uemura T; Oguri T; Maeno K; Sone K; Takeuchi A; Fukuda S; Kunii E; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1229-1239. PubMed ID: 31529207
[TBL] [Abstract][Full Text] [Related]
12. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
13. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Hoff PM
Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Nakayama T; Noguchi S
Oncologist; 2010; 15(1):26-36. PubMed ID: 20080863
[TBL] [Abstract][Full Text] [Related]
15. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
16. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.
Nakano J; Huang C; Liu D; Masuya D; Nakashima T; Yokomise H; Ueno M; Wada H; Fukushima M
Br J Cancer; 2006 Sep; 95(5):607-15. PubMed ID: 16880781
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.
Tanaka F; Yanagihara K; Otake Y; Miyahara R; Wada H
Cancer Sci; 2004 Apr; 95(4):371-6. PubMed ID: 15072598
[TBL] [Abstract][Full Text] [Related]
18. The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer.
Langer CJ
Lung Cancer; 2001 Nov; 34(2):297-303. PubMed ID: 11679189
[TBL] [Abstract][Full Text] [Related]
19. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review].
Tanaka F; Wada H
Gan To Kagaku Ryoho; 2006 Mar; 33(3):300-6. PubMed ID: 16531708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
